Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Nektar is a clinical-stage biopharmaceutical company focused on immunotherapy. Its primary assets include rezpegaldesleukin (autoimmune diseases), NKTR-0165 (autoimmune), and NKTR-255 (oncology). The company recently sold its manufacturing facility in Huntsville, Alabama, to Gannet BioChem in December 2024, transitioning to a contract manufacturing model.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Dec 31, 2024 (Balance Sheet) |
|---|---|---|---|
| Total Revenue | $11,175 | $21,635 | — |
| Net Loss | $(41,593) | $(92,475) | — |
| Loss Per Share (Basic & Diluted) | $(2.95) | $(6.57) | — |
| Cash and Cash Equivalents | — | — | $42,988 |
| Short-term Investments | — | — | $132,915 |
| Total Cash & Investments | — | — | $175,903 |
| Total Liabilities | — | — | $231,745 |
| Stockholders' Equity (Deficit) | — | — | $(24,211) |
Note: Revenue consists entirely of non-cash royalty revenue related to the sale of future royalties. Product sales were $0 due to the sale of the manufacturing facility.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 52% year-over-year for the six months ended June 30, 2025 ($21.6M vs. $45.1M). This is primarily due to the cessation of product sales following the facility sale and a decrease in non-cash royalty revenue.
- Operating Expenses: Total operating costs decreased 21% year-over-year ($102.4M vs. $130.3M). This reduction was driven by a 96% decrease in restructuring and impairment charges ($0.6M vs. $14.3M), as significant impairment charges were recorded in 2024 but not in 2025.
- Net Loss: Net loss increased slightly by 4% for the six-month period ($92.5M vs. $89.2M), largely due to a $6.8M loss from the equity method investment in Gannet BioChem, which did not exist in the prior year.
- Capital Structure: The company executed a 1-for-15 reverse stock split effective June 8, 2025. All share and per-share data have been retrospectively adjusted.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management estimates sufficient working capital to fund operations for at least the next twelve months. As of June 30, 2025, the company held approximately $175.9 million in cash and investments.
- Subsequent Financing: On July 2, 2025, Nektar completed an underwritten public offering of 4,893,618 shares at $23.50 per share, raising net proceeds of approximately $107.5 million.
- Shelf Registration: A shelf registration statement effective April 1, 2025, allows for the sale of up to $300 million in securities.
Key Developments:
- Rezpegaldesleukin: Phase 2b REZOLVE-AD trial met its primary endpoint (EASI improvement) and key secondary endpoints. FDA granted Fast Track designation for atopic dermatitis and alopecia areata.
- NKTR-255: Phase 2 study in large B-cell lymphoma showed improved complete response rates compared to placebo. Topline data expected from the JAVELIN Bladder Medley study in Q3 2025.
Risks and Contingencies:
- Litigation: Ongoing lawsuit against Eli Lilly regarding the termination of their collaboration agreement. A jury trial is scheduled for October 27, 2025. No liability has been recorded.
- Dependency: High dependence on the success of rezpegaldesleukin. Failure in clinical trials would significantly harm the business.
- Manufacturing: Reliance on Gannet BioChem for the supply of PEG reagents following the sale of the Huntsville facility.
- Profitability: The company expects to continue incurring substantial net losses and may not achieve profitability in the future.
Investor Verification Checklist
- Cash Runway: Verify the impact of the July 2025 equity offering ($107.5M net proceeds) on the company's liquidity and operational runway beyond the stated 12-month estimate.
- Rezpegaldesleukin Data: Review the full clinical data release for the REZOLVE-AD trial to assess the durability of the response and safety profile for Phase 3 planning.
- Litigation Status: Monitor the status of the Eli Lilly lawsuit and any potential settlement or judgment impacts on the rezpegaldesleukin program.
- Equity Method Investment: Analyze the financial performance of Gannet BioChem and the continued impact of the HLBV accounting method on Nektar's net loss.
- Reverse Split Impact: Confirm the post-split share count and trading liquidity following the 1-for-15 reverse stock split.